Belite Bio (BLTE) EPS (Basic) (2022 - 2026)
Belite Bio's (BLTE) quarterly EPS (Basic) came in at -$0.0 in Q1 2026, down 112.12% year-on-year from $0.0 in Q1 2025, and down 108.14% quarter-over-quarter from $0.0 in Q4 2025.
Belite Bio (BLTE) EPS (Basic) (2022 - 2026) Analysis & Trends
Belite Bio's EPS (Basic) history runs 5 years deep, the most recent figure standing at -$0.0 for Q1 2026.
- On a quarterly basis, EPS (Basic) fell 112.12% year-over-year to -$0.0 in Q1 2026; TTM through Mar 2026 was $0.0, a 98.16% decrease from a year earlier, with the FY2025 full-year figure at $0.0, up 78.25% from the prior year.
- EPS (Basic) eased to -$0.0 in Q1 2026 per BLTE's latest filing, from $0.0 in the prior quarter.
- Across five years, EPS (Basic) topped out at $0.0 in Q4 2025 and bottomed at -$0.0 in Q2 2025.
- The 5-year median for EPS (Basic) is $0.0 (2024), against an average of $0.0.
- Biggest YoY gain for EPS (Basic) was 264.17% in 2023; the steepest drop was 225.98% in 2023.
- Year by year, EPS (Basic) stood at $0.0 in 2022, then slumped by 169.55% to -$0.0 in 2023, then surged by 211.47% to $0.0 in 2024, then soared by 99.18% to $0.0 in 2025, then plunged by 108.14% to -$0.0 in 2026.
- Per Business Quant, the three latest BLTE EPS (Basic) figures stand at -$0.0 (Q1 2026), $0.0 (Q4 2025), and $0.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 0.00 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 0.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 0.16 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 4.06 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 6.99 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 0.00 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 5.90 |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -2.29 |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 1.55 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.00 |
| Dec 31, 2025 | 0.00 |
| Sep 30, 2025 | 0.00 |
| Jun 30, 2025 | 0.00 |
| Mar 31, 2025 | 0.00 |
| Dec 31, 2024 | 0.00 |
| Sep 30, 2024 | 0.00 |
| Jun 30, 2024 | 0.00 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.00 |
| Sep 30, 2023 | 0.00 |
| Jun 30, 2023 | 0.00 |
| Mar 31, 2023 | 0.00 |
| Dec 31, 2022 | 0.00 |
| Sep 30, 2022 | 0.00 |
| Jun 30, 2022 | 0.00 |